Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 9, 2015, Pages 1583-1588

  Chen, Yi Bin ^a   Li, Shuli ^b   Fisher, David C ^b   Driscoll, Jessica ^a   Del Rio, Candice ^a   Abramson, Jeremy ^a   Armand, Philippe ^b   Barnes, Jeffrey ^a   Brown, Jennifer ^b   Cutler, Corey ^b   El Jawahri, Areej ^a   Ho, Vincent T ^b   Hochberg, Ephraim ^a   McAfee, Steven ^a   Takvorian, Ronald ^a   Spitzer, Thomas R ^a   Antin, Joseph H ^b   Soiffer, Robert ^b   Jacobsen, Eric ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Auto allo; Lymphoma; Reduced intensity conditioning; Tandem transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; METHOTREXATE; RAPAMYCIN; TACROLIMUS; ANTINEOPLASTIC AGENT; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; LYMPHOMA; MALE; MORTALITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RELAPSE; UNRELATED DONORS; ALLOGRAFT; ANALOGS AND DERIVATIVES; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; MIDDLE AGED; MULTICENTER STUDY; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; AGED; ALLOGRAFTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOGRAFTS; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; SIROLIMUS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TACROLIMUS; VIDARABINE;

EID: 84938999316     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.05.016     Document Type: Article

References (30)

1. Touzeau C., Leux C., Bouabdallah R., et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol 2014, 93:233-242.
2. Geisler C.H., Kolstad A., Laurell A., et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012, 158:355-362.
3. d'Amore F., Relander T., Lauritzsen G.F., et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012, 30:3093-3099.
4. Telio D., Fernandes K., Ma C., et al. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma 2012, 53:836-841.
5. Guglielmi C., Gomez F., Philip T., et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998, 16:3264-3269.
6. Papageorgiou S.G., Cwynarski K., Kottaridis P.D. The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL). Bone Marrow Transplant 2013, 48:1271-1278.
7. Sureda A., Domenech E., Schmitz N., et al. The role of allogeneic stem cell transplantation in Hodgkin's lymphoma. Curr Treat Opt Oncol 2014, 15:238-247.
8. Hosing C., Champlin R.E. Stem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol 2011, 22:1471-1477.
9. Cohen J.B., Burns L.J., Bachanova V. Role of allogeneic stem cell transplantation in mantle cell lymphoma. Eur J Haematol 2015, 94:290-297.
10. Bacher U., Klyuchnikov E., Le-Rademacher J., et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. Blood 2012, 120:4256-4262.
11. Hari P., Carreras J., Zhang M.J., et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008, 14:236-245.
12. Gahrton G., Iacobelli S., Bjorkstrand B., et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013, 121:5055-5063.
13. Bjorkstrand B., Iacobelli S., Hegenbart U., et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011, 29:3016-3022.
14. Krishnan A., Pasquini M.C., Logan B., et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, 12:1195-1203.
15. Rosinol L., Perez-Simon J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
16. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
17. Carella A.M., Cavaliere M., Lerma E., et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000, 18:3918-3924.
18. Gutman J.A., Bearman S.I., Nieto Y., et al. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplant 2005, 36:443-451.
19. Cohen S., Kiss T., Lachance S., et al. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant 2012, 18:951-957.
20. Crocchiolo R., Castagna L., Furst S., El-Cheikh J., Faucher C., Oudin C., et al. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2013, 48:249-252.
21. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
22. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
23. Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
24. Chen Y.B., Hochberg E.P., Feng Y., et al. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010, 51:789-796.
25. Mounier N., Canals C., Gisselbrecht C., et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012, 18:788-793.
26. Redondo A.M., Pomares H., Vidal M.J., et al. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. Br J Haematol 2014, 164:668-674.
27. Hamadani M., Hari P.N., Zhang Y., et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014, 20:1729-1736.
28. Armand P., Welch S., Kim H.T., et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol 2013, 160:608-617.
29. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015, 125:3393-3400.
30. Maus M.V., Grupp S.A., Porter D.L., June C.H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014, 123:2625-2635.